WNWilfred Ngwa

Wilfred Ngwa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wilfred Ngwa has a total of 171 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Hypofractionated radiotherapy for localised prostate cancer: the HypoAfrica experience

    by Azeezat Ajose, Lensa Seyoum Keno, Adedayo Joseph, Solomon Kibbude, Abba Aji Mallum, Twalib Ngoma, Samuel Adeneye, Awusi Kavuma, Jumaa Kisukari, Thokozani Mkhize, et al.

    Hypofractionated radiotherapy for localised prostate cancer: the HypoAfrica experience Azeezat Ajose1, Lensa Seyoum Keno2, Adedayo Joseph1, Solomon Kibudde3,

  • Open Access

    Multiscale Segmentation-Guided Diffusion Model for CBCT-to-CT Synthesis

    by Yike Guo, Yi Luo, Hamed Hooshangnejad, Rui Zhang, Xue Feng, Quan Chen, Wilfred Ngwa, Kai Ding

    To improve synthetic CT (sCT) generation from cone-beam CT (CBCT) in radiotherapy, we propose a multiscale segmentation-guided diffusion framework. The proposed model integrates anatomical priors across multiple spatial resolutions through a segmentation mask pyramid and introduces a scale-specific loss function to guide learning at each level. When evaluated on the SynthRAD2023 brain dataset, our model achieves a mean absolute error (MAE) of 61.82 HU, a peak signal-to-noise ratio (PSNR) of 32.05 dB, and a structural similarity index (SSIM) of 0.90, outperforming baseline models. These results suggest that multiscale anatomical guidance can improve the fidelity and anatomical consistency of sCT images, thus facilitating high-quality CBCT-to-CT translation in radiotherapy applications.


  • Open Access

    Deep Learning for CT Synthesis in Radiotherapy

    by Yike Guo, Yi Luo, Hamed Hooshangnejad, Rui Zhang, Xue Feng, Quan Chen, Wilfred Ngwa, Kai Ding

    With the rapid development of artificial intelligence (AI), various deep learning (DL) methods have been introduced into radiation oncology. Among them, the generation of synthetic Computed Tomography (sCT) images has attracted increasing attention, as it supports different clinical scenarios, from image-guided adaptive radiotherapy (IGART) to the simulation-free workflow. This review provides a comprehensive overview of recent studies on DL-based sCT synthesis in radiotherapy from multiple imaging modalities, including Cone-Beam CT (CBCT), Magnetic Resonance Imaging (MRI), and diagnostic CT, and discusses their clinical applications in CBCT-based online adaptive radiotherapy, MRI-guided radiotherapy, and simulation-free workflows. We also examine the architectures of representative DL models such as convolutional neural networks (CNNs) and generative adversarial networks (GANs) and summarize emerging training strategies. Finally, we discuss current challenges of clinical translation of DL algorithms into clinical practice and suggest potential directions for future research. Overall, this paper highlights the potential of AI-driven sCT generation to advance treatment planning by reducing imaging burden, improving dose accuracy, and accelerating workflow efficiency, thus ultimately improving the treatment outcome of patient care.


  • Open Access

    Leveraging the Immune Response from LIFE Biomaterial and Photon-Flash in Pre-Clinical Pancreatic Cancer Treatment

    by Michele Moreau, Katelyn Kelly, Serena Mao, Debarghya China, Girmachew Wasihun, Aditya Pandya, MohammadAli Tajik-Mansoury, Daniel Sforza, Devin Miles, Amol K. Narang, et al.

    Pre-clinical animal studies evaluating the ‘flash effect’ caused by ultra-high dose rate (≥40 Gy/s) favorably spares normal tissue from radiation-caused toxicity while maintaining anti-tumor effects like conventional (CONV) radiation. The goal of this study is to leverage an immune response resulting from the treatment combination of flash radiotherapy (Flash-RT) and LIFE (liquid immunogenic fiducial eluter) biomaterial incorporating an anti-mouse CD40 monoclonal antibody to enhance the therapeutic ratio in pancreatic cancer. Methods: A small animal FLASH radiation research platform (FLASH-SARRP) was utilized to deliver both ultra-high and CONV dose-rate irradiation to treat syngeneic subcutaneous pancreatic tumors generated in 8–10-week-old male and female C57BL6 mice. The efficacy of FLASH versus CONV radiotherapy (RT) at varying doses of 5, 8, 10, and 15 Gy delivered in a single fraction was evaluated by assessing tumor growth and mice survival over time or comparing tumor weight at 10 days post-treatment. Results: Similar tumor control capability was observed by the high-dose rate and conventional RT related to the control group. Nevertheless, longer survival was observed for the FLASH group at 5 Gy compared to CONV and control at either 5 Gy, 10 Gy, or 15 Gy doses. Multiplex immunofluorescence and immunohistochemistry results showed higher T-cell infiltration within the combination of RT (either FLASH or CONV) and LIFE biomaterial-treated tumors compared to the control cohort. Conclusions: This animal study serves as an impetus for future studies leveraging the immune response using the combination of FLASH and LIFE Biomaterial to enhance the efficacy of pancreatic cancer treatment.


  • Open Access

    From farm to bedside: Potential of medical cannabis in global health

    by Maureen Bilinga Tendwa, Tejaswini Appidi, Brylyne Chitsunge, Michele Moreau, Blessed Okole, Lonji Kalombo, Abba Mallum, Twalib Ngoma, Daniel P. Weadock, Eric Tanifum, et al.


  • Open Access

    Leveraging the Immune Response from LIFE Biomaterial and Photon-Flash in Pre-Clinical Pancreatic Cancer Treatment

    by Michele Moreau, Katelyn Kelly, Serena Mao, Debarghya China, Girmachew Wasihun, Aditya Pandya, Ehsan Tajik-Mansoury, Daniel Sforza, Devin Miles, Amol K. Narang, et al.

    Pre-clinical animal studies evaluating the ‘flash effect’ caused by ultra-high dose rate (>=40Gy/s) favorably spares normal tissue from radiation-caused toxicity while maintaining anti-tumor effect like conventional (CONV) radiation. The goal of this study is to leverage an immune response resulting from the treatment combination of flash radiotherapy (Flash-RT) and LIFE (liquid immunogenic fiducial eluter) biomaterial incorporating an anti-mouse CD40 monoclonal antibody to enhance the therapeutic ratio in pancreatic cancer. Methods: A small animal FLASH radiation research platform (FLASH-SARRP) was utilized to deliver both ultrahigh and CONV dose-rate irradiation to treat syngeneic subcutaneous pancreatic tumors generated in 8-10-week-old female C57BL6 mice. The efficacy of FLASH versus CONV radiotherapy (RT) at varying doses of 5, 8, 10, and 15Gy delivered in a single fraction was evaluated by assessing tumor growth and mice survival over time or comparing tumor weight at 10 days post-treatment. Results: Similar tumor control capability was observed from both FLASH and CONV RT compared to the control group. However, longer survival was observed for the FLASH group at 5Gy compared to CONV and control at either 5Gy, 10Gy, or 15Gy dose. Multiplex immunofluorescence and immunohistochemistry results showed higher T-cells infiltration within the combination of RT (either FLASH or CONV) and LIFE biomaterial-treated tumors compared to the control cohort. Conclusions: This animal study serves as an impetus for future studies leveraging the immune response using the combination of FLASH and LIFE Biomaterial to enhance the efficacy of pancreatic cancer treatment.


  • Open Access

    A Language Vision Model Approach for Automated Tumor Contouring in Radiation Oncology

    by Yi Luo, Hamed Hooshangnejad, Xue Feng, Gaofeng Huang, Xiaojian Chen, Rui Zhang, Quan Chen, Wil Ngwa, Kai Ding

    Background: Lung cancer ranks as the leading cause of cancer-related mortality worldwide. The complexity of tumor delineation, crucial for radiation therapy, requires expertise often unavailable in resource-limited settings. Artificial Intelligence (AI), particularly with advancements in deep learning (DL) and natural language processing (NLP), offers potential solutions yet is challenged by high false positive rates. Purpose: The Oncology Contouring Copilot (OCC) system is developed to leverage oncologist expertise for precise tumor contouring using textual descriptions, aiming to increase the efficiency of oncological workflows by combining the strengths of AI with human oversight. Methods: Our OCC system initially identifies nodule candidates from CT scans. Employing Language Vision Models (LVMs) like GPT-4V, OCC then effectively reduces false positives with clinical descriptive texts, merging textual and visual data to automate tumor delineation, designed to elevate the quality of oncology care by incorporating knowledge from experienced domain experts. Results: The deployment of the OCC system resulted in a 35.0% reduction in the false discovery rate, a 72.4% decrease in false positives per scan, and an F1-score of 0.652 across our dataset for unbiased evaluation. Conclusions: OCC represents a significant advance in oncology care, particularly through the use of the latest LVMs, improving contouring results by (1) streamlining oncology treatment workflows by optimizing tumor delineation and reducing manual processes; (2) offering a scalable and intuitive framework to reduce false positives in radiotherapy planning using LVMs; (3) introducing novel medical language vision prompt techniques to minimize LVM hallucinations with ablation study; and (4) conducting a comparative analysis of LVMs, highlighting their potential in addressing medical language vision challenges.


  • Open Access

    Mesoporous Polydopamine Nano-Bowls Demonstrate a High Entrapment Efficiency and pH-Responsive Release of Paclitaxel for Suppressing A549 Lung Cancer Cell Proliferation In Vitro

    by Lindokuhle M. Ngema, Shahinur Acter, Samson A. Adeyemi, Thashree Marimuthu, Mershen Govender, Wilfred Ngwa, Yahya E. Choonara

    Background: The effectiveness of paclitaxel (PTX) in treating non-small-cell lung carcinoma (NSCLC) is restricted by its poor pharmacokinetic profile and side effects. This limitation stems from the lack of a suitable delivery vector to efficiently target cancer cells. Therefore, there is a critical need to develop an efficient carrier for the optimised delivery of PTX in NSCLC therapy. Methods: The present study describes the fabrication of mesoporous polydopamine (mPDA) nano-bowls via an emulsion-induced interfacial anisotropic assembly method, designed for efficient entrapment of PTX and pH-responsive release behaviour. Results: The nano-bowls depicted a typical bowl-like shape, with connecting mesoporous channels and a central hollow cavity, allowing optimal loading of PTX. The fabricated nanocarrier system, mPDA-PTX-nb, had a mean hydrodynamic bowl diameter of 200.4 ± 5.2 nm and a surface charge of −39.2 ± 1.3 mV. The entrapment efficiency of PTX within the nano-bowls was found to be 95.7%, with a corresponding release of 85.1% achieved at the acidic pH 5.9 (simulated tumour microenvironment) at 48 h. Drug release was best fitted to the Peppas–Sahlin model, indicating the involvement of both diffusion and relaxation mechanisms. Treatment with mPDA-PTX-nb significantly suppressed A549 lung cancer cell proliferation at 48 and 72 h, resulting in cell viability of 14.0% and 9.3%, respectively, at the highest concentration (100 µg/mL). Conclusions: These results highlight the potential of mPDA-PTX-nb as an effective nanocarrier for PTX, promoting enhanced anti-proliferative effects in NSCLC therapy.


  • Open Access

    Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY)

    by Michele Moreau, Debarghya China, Gnagna Sy, Kai Ding, Wilfred Ngwa

    Smart radiotherapy biomaterials (SRBs) include seed and liquid biomaterials designed to be employed as fiducial markers during radiotherapy while also delivering therapeutic drug payloads to enhance treatment outcomes. In this study, we investigate a novel Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY) biomaterial, which can be loaded with immunoadjuvants (anti-CD40 monoclonal antibody or Caflanone (FBL-03G)) at the point of care. The CLARITY biomaterial was investigated in an animal model of pancreatic cancer using C57BL6 mice. Mice were imaged before and at different points of time post-treatment to evaluate the potential of CLARITY biomaterial to provide imaging contrast similar to fiducials. This study also used cadavers to assess CLARITY’s potential to provide imaging contrast in humans. Results showed imaging contrast from computed tomography (CT) and magnetic resonance imaging (MRI) modalities for up to 30 days post-treatment, demonstrating potential for use as fiducials. A significant increase in survival (***, p = 0.0006) was observed for mice treated with CLARITY biomaterial loaded with immunoadjuvant for up to 10 weeks post-treatment compared to those without treatment. These initial results demonstrate the potential of CLARITY biomaterial to serve as a smart multifunctional radiotherapy biomaterial and provide the impetus for further development and optimization as a point-of-care technology for combination radiotherapy and immunotherapy.